<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085991</url>
  </required_header>
  <id_info>
    <org_study_id>CROSSBOW</org_study_id>
    <nct_id>NCT04085991</nct_id>
  </id_info>
  <brief_title>Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer</brief_title>
  <acronym>CROSSBOW</acronym>
  <official_title>Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Mortimer B. Davis - Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Mortimer B. Davis - Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-arm, open-label, phase II trial in 200 competent adult male patients with Eastern
      Cooperative Oncology Group performance status (ECOG PS) of 0-3 and progressive metastatic
      prostate cancer, failing, failed, refused, not eligible for or no access to further approved
      lines of therapy. Patients will undergo sequential FDG positron emission tomography (PET) and
      18F-DCFPyL PET to assess FDG/DCFPyL concordance fraction. Patients with DCFPyL/FDG
      concordance of 50% or greater will be treated with 131I-PSMA-1095 radioligand therapy (RLT).
      Best post-treatment serum prostate specific antigen response will be compared to concordance
      fraction.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum prostate specific antigen (PSA)</measure>
    <time_frame>3 months post last dose of RLT</time_frame>
    <description>The best serum prostate specific antigen (PSA) response will be calculated for each patient as: pre-treatment PSA minus lowest post-treatment PSA divided by pre-treatment PSA. Best PSA response will be reported as percent reduction (or increase) from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>3 months post last dose of RLT</time_frame>
    <description>Adverse events as per CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Prostatic Neoplasms</condition>
  <condition>Metastatic Prostate Cancer</condition>
  <condition>Metastatic Prostatic Adenocarcinoma</condition>
  <condition>Metastatic Prostate Carcinoma in the Soft Tissue</condition>
  <arm_group>
    <arm_group_label>131I-PSMA-1095 Radioligand Therapy (RLT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous injection of 100 mCi of 131I-PSMA-1095 RLT, Q8 weeks up to a maximum of 4 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>131I-PSMA-1095 Radioligand Therapy (RLT)</intervention_name>
    <description>Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.</description>
    <arm_group_label>131I-PSMA-1095 Radioligand Therapy (RLT)</arm_group_label>
    <other_name>PSMA RLT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Age 18 years or older

          -  Documented metastatic adenocarcinoma of the prostate

          -  Under active medical oncology care

          -  ECOG performance status 0 - 3, inclusive

          -  Able to understand and provide written informed consent

          -  Able to tolerate the physical requirements of two PET/CT scans including lying for up
             to 30 minutes

          -  Progressive disease on any of: bone scan, CT, MRI or serum PSA as judged by the
             investigator

          -  Serum prostate specific antigen â‰¥ 5 ng/ml at baseline or CT/MRI soft-tissue measurable
             disease as per RECIST v1.1

          -  Failed, failing, refused, no access to or not eligible for any approved prostate
             cancer therapies including but not limited to: ADT, NAAD (e.g., abiraterone,
             enzalutamide, darolutamide or apalutamide), docetaxel, cabazitaxel, radium-223 and
             oligometastatic RTX

          -  Life expectancy of at least 3 months as judged by the investigator

        Exclusion Criteria:

          -  Medically unstable (e.g. acute cardiac or respiratory distress or hypotensive)

          -  Exceeding the weight limit of the PET/CT bed (approximately 400 lbs.) or who cannot
             fit through the PET/CT bore (approximately 70 cm diameter)

          -  Unmanageable claustrophobia

          -  Prior failure of PSMA RLT

          -  Prior hemi-body irradiation

          -  Impaired organ function as evidenced by any of the following laboratory values:

               -  Absolute neutrophil count &lt; 1.5 x109/L

               -  Platelet count &lt; 75 x109/L

               -  Hemoglobin &lt; 85 g/L

               -  Albumin &lt; 2.5 g/dL (25 g/L)

               -  Total bilirubin &gt; 2 x ULN (unless in instances of Gilbert's disease)

               -  AST or ALT &gt; 2.5 x ULN (or &gt; 5.0 x ULN in the presence of liver metastases)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male only.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Probst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Probst, MD</last_name>
    <phone>5143408222</phone>
    <phone_ext>25734</phone_ext>
    <email>nukesmd@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stephan Probst</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephan Probst, MD</last_name>
      <phone>5143408222</phone>
      <phone_ext>25374</phone_ext>
      <email>nukesmd@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 8, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>March 8, 2020</last_update_submitted>
  <last_update_submitted_qc>March 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Mortimer B. Davis - Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Stephan Probst, MD</investigator_full_name>
    <investigator_title>Chief of Nuclear Medicine</investigator_title>
  </responsible_party>
  <keyword>Radioligand therapy</keyword>
  <keyword>PSMA</keyword>
  <keyword>PSMA therapy</keyword>
  <keyword>1095</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

